Natera, Inc. (NASDAQ:NTRA – Get Free Report) insider Solomon Moshkevich sold 80,000 shares of the stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $90.82, for a total value of $7,265,600.00. Following the completion of the transaction, the insider now directly owns 117,560 shares of the company’s stock, valued at $10,676,799.20. The sale was disclosed in a filing with the SEC, which is available through this link.
Natera Price Performance
NTRA opened at $87.28 on Friday. The stock has a fifty day moving average of $85.74 and a 200-day moving average of $65.57. The firm has a market capitalization of $10.54 billion, a P/E ratio of -23.03 and a beta of 1.37. Natera, Inc. has a 12-month low of $36.90 and a 12-month high of $98.82. The company has a quick ratio of 3.96, a current ratio of 4.10 and a debt-to-equity ratio of 0.37.
Natera (NASDAQ:NTRA – Get Free Report) last released its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.09. The company had revenue of $311.11 million during the quarter, compared to analyst estimates of $300.38 million. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. Equities analysts forecast that Natera, Inc. will post -2.35 EPS for the current fiscal year.
Institutional Trading of Natera
Analyst Ratings Changes
NTRA has been the subject of a number of recent analyst reports. Piper Sandler increased their price objective on Natera from $70.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th. Raymond James lowered Natera from a “strong-buy” rating to an “outperform” rating and increased their price target for the company from $68.00 to $85.00 in a research note on Tuesday, February 20th. BTIG Research increased their price target on Natera from $75.00 to $85.00 and gave the company a “buy” rating in a research note on Friday, December 29th. Stephens reaffirmed an “overweight” rating and set a $78.00 price target on shares of Natera in a research note on Tuesday, January 30th. Finally, Craig Hallum initiated coverage on Natera in a research note on Monday, April 8th. They set a “buy” rating and a $117.00 price target for the company. One investment analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $86.40.
Read Our Latest Stock Analysis on NTRA
About Natera
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
See Also
- Five stocks we like better than Natera
- Airline Stocks – Top Airline Stocks to Buy Now
- Comprehensive PepsiCo Stock Analysis
- How to Invest in Blue Chip Stocks
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- What is a Stock Market Index and How Do You Use Them?
- Bear Market Funds to Watch This Year
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.